Chloroquine and COVID-19: Should We Care about Ototoxicity?
Identifieur interne : 000F21 ( Main/Corpus ); précédent : 000F20; suivant : 000F22Chloroquine and COVID-19: Should We Care about Ototoxicity?
Auteurs : Eduardo Machado Rossi Monteiro ; Maria Fernanda Lima Nascimento ; Thayanne Rachel Cangussu Brito ; Marcos Correia Lima ; Laura Rodrigues Sefair ; Maisa Mendes PedrosaSource :
- International archives of otorhinolaryngology [ 1809-9777 ] ; 2020.
Abstract
Introduction Severe acute respiratory syndrome coronavirus 2 was first described in December 2019 in China leading to a Public Health Emergency of International Concern. It was named by the World Health Organization as Coronavirus Disease 2019 (COVID-19), and it garnered unprecedented attention from public health researchers around the world, and studies analyzing chloroquine and hydroxychloroquine as a possible therapy have arisen in the last 2 months. Objective To review the literature and describe updated facts about the ototoxicity of chloroquine and hydroxychloroquine, an important side effect that can be present in patients with COVID-19 treated with these drugs. Data Synthesis The most typical treatment regimen is 5 days of hydroxychloroquine at daily doses of 400 to 600 mg. There is no randomized clinical trial that can prove so far the efficacy of this medication, and few studies have evaluated adverse events potentially linked to their use in patients with COVID-19. While there is no concrete evidence on the incidence of ototoxicity using chloroquine in the short term, we need to consider that, as a pandemic disease, millions of patients with COVID-19 may receive this treatment, and ototoxicity can be a possible adverse event. Conclusion Despite the urgent global situation caused by the COVID-19, the risk of irreversible hearing loss may outweigh the unproven benefit of using hydroxychloroquine or chloroquine, especially in patients with mild forms of COVID-19, who may be cured with supportive treatment. The potential hearing loss that can be caused by these medications may advise against their use in COVID-19 patients.
DOI: 10.1055/s-0040-1714142
PubMed: 32774508
PubMed Central: PMC7402412
Links to Exploration step
pubmed:32774508Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chloroquine and COVID-19: Should We Care about Ototoxicity?</title><author><name sortKey="Monteiro, Eduardo Machado Rossi" sort="Monteiro, Eduardo Machado Rossi" uniqKey="Monteiro E" first="Eduardo Machado Rossi" last="Monteiro">Eduardo Machado Rossi Monteiro</name><affiliation><nlm:affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Nascimento, Maria Fernanda Lima" sort="Nascimento, Maria Fernanda Lima" uniqKey="Nascimento M" first="Maria Fernanda Lima" last="Nascimento">Maria Fernanda Lima Nascimento</name><affiliation><nlm:affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Brito, Thayanne Rachel Cangussu" sort="Brito, Thayanne Rachel Cangussu" uniqKey="Brito T" first="Thayanne Rachel Cangussu" last="Brito">Thayanne Rachel Cangussu Brito</name><affiliation><nlm:affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Lima, Marcos Correia" sort="Lima, Marcos Correia" uniqKey="Lima M" first="Marcos Correia" last="Lima">Marcos Correia Lima</name><affiliation><nlm:affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Sefair, Laura Rodrigues" sort="Sefair, Laura Rodrigues" uniqKey="Sefair L" first="Laura Rodrigues" last="Sefair">Laura Rodrigues Sefair</name><affiliation><nlm:affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Pedrosa, Maisa Mendes" sort="Pedrosa, Maisa Mendes" uniqKey="Pedrosa M" first="Maisa Mendes" last="Pedrosa">Maisa Mendes Pedrosa</name><affiliation><nlm:affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32774508</idno><idno type="pmid">32774508</idno><idno type="doi">10.1055/s-0040-1714142</idno><idno type="pmc">PMC7402412</idno><idno type="wicri:Area/Main/Corpus">000F21</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000F21</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Chloroquine and COVID-19: Should We Care about Ototoxicity?</title><author><name sortKey="Monteiro, Eduardo Machado Rossi" sort="Monteiro, Eduardo Machado Rossi" uniqKey="Monteiro E" first="Eduardo Machado Rossi" last="Monteiro">Eduardo Machado Rossi Monteiro</name><affiliation><nlm:affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Nascimento, Maria Fernanda Lima" sort="Nascimento, Maria Fernanda Lima" uniqKey="Nascimento M" first="Maria Fernanda Lima" last="Nascimento">Maria Fernanda Lima Nascimento</name><affiliation><nlm:affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Brito, Thayanne Rachel Cangussu" sort="Brito, Thayanne Rachel Cangussu" uniqKey="Brito T" first="Thayanne Rachel Cangussu" last="Brito">Thayanne Rachel Cangussu Brito</name><affiliation><nlm:affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Lima, Marcos Correia" sort="Lima, Marcos Correia" uniqKey="Lima M" first="Marcos Correia" last="Lima">Marcos Correia Lima</name><affiliation><nlm:affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Sefair, Laura Rodrigues" sort="Sefair, Laura Rodrigues" uniqKey="Sefair L" first="Laura Rodrigues" last="Sefair">Laura Rodrigues Sefair</name><affiliation><nlm:affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Pedrosa, Maisa Mendes" sort="Pedrosa, Maisa Mendes" uniqKey="Pedrosa M" first="Maisa Mendes" last="Pedrosa">Maisa Mendes Pedrosa</name><affiliation><nlm:affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</nlm:affiliation></affiliation></author></analytic><series><title level="j">International archives of otorhinolaryngology</title><idno type="ISSN">1809-9777</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><b>Introduction</b> Severe acute respiratory syndrome coronavirus 2 was first described in December 2019 in China leading to a Public Health Emergency of International Concern. It was named by the World Health Organization as Coronavirus Disease 2019 (COVID-19), and it garnered unprecedented attention from public health researchers around the world, and studies analyzing chloroquine and hydroxychloroquine as a possible therapy have arisen in the last 2 months. <b>Objective</b> To review the literature and describe updated facts about the ototoxicity of chloroquine and hydroxychloroquine, an important side effect that can be present in patients with COVID-19 treated with these drugs. <b>Data Synthesis</b> The most typical treatment regimen is 5 days of hydroxychloroquine at daily doses of 400 to 600 mg. There is no randomized clinical trial that can prove so far the efficacy of this medication, and few studies have evaluated adverse events potentially linked to their use in patients with COVID-19. While there is no concrete evidence on the incidence of ototoxicity using chloroquine in the short term, we need to consider that, as a pandemic disease, millions of patients with COVID-19 may receive this treatment, and ototoxicity can be a possible adverse event. <b>Conclusion</b> Despite the urgent global situation caused by the COVID-19, the risk of irreversible hearing loss may outweigh the unproven benefit of using hydroxychloroquine or chloroquine, especially in patients with mild forms of COVID-19, who may be cured with supportive treatment. The potential hearing loss that can be caused by these medications may advise against their use in COVID-19 patients.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32774508</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1809-9777</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>International archives of otorhinolaryngology</Title><ISOAbbreviation>Int Arch Otorhinolaryngol</ISOAbbreviation></Journal><ArticleTitle>Chloroquine and COVID-19: Should We Care about Ototoxicity?</ArticleTitle><Pagination><MedlinePgn>e359-e363</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0040-1714142</ELocationID><Abstract><AbstractText><b>Introduction</b> Severe acute respiratory syndrome coronavirus 2 was first described in December 2019 in China leading to a Public Health Emergency of International Concern. It was named by the World Health Organization as Coronavirus Disease 2019 (COVID-19), and it garnered unprecedented attention from public health researchers around the world, and studies analyzing chloroquine and hydroxychloroquine as a possible therapy have arisen in the last 2 months. <b>Objective</b> To review the literature and describe updated facts about the ototoxicity of chloroquine and hydroxychloroquine, an important side effect that can be present in patients with COVID-19 treated with these drugs. <b>Data Synthesis</b> The most typical treatment regimen is 5 days of hydroxychloroquine at daily doses of 400 to 600 mg. There is no randomized clinical trial that can prove so far the efficacy of this medication, and few studies have evaluated adverse events potentially linked to their use in patients with COVID-19. While there is no concrete evidence on the incidence of ototoxicity using chloroquine in the short term, we need to consider that, as a pandemic disease, millions of patients with COVID-19 may receive this treatment, and ototoxicity can be a possible adverse event. <b>Conclusion</b> Despite the urgent global situation caused by the COVID-19, the risk of irreversible hearing loss may outweigh the unproven benefit of using hydroxychloroquine or chloroquine, especially in patients with mild forms of COVID-19, who may be cured with supportive treatment. The potential hearing loss that can be caused by these medications may advise against their use in COVID-19 patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Monteiro</LastName><ForeName>Eduardo Machado Rossi</ForeName><Initials>EMR</Initials><Identifier Source="ORCID">0000-0002-9082-3232</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nascimento</LastName><ForeName>Maria Fernanda Lima</ForeName><Initials>MFL</Initials><Identifier Source="ORCID">0000-0001-7215-3549</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brito</LastName><ForeName>Thayanne Rachel Cangussu</ForeName><Initials>TRC</Initials><Identifier Source="ORCID">0000-0003-4874-6904</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lima</LastName><ForeName>Marcos Correia</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-6398-2019</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sefair</LastName><ForeName>Laura Rodrigues</ForeName><Initials>LR</Initials><Identifier Source="ORCID">0000-0002-0165-6162</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedrosa</LastName><ForeName>Maisa Mendes</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-9070-6247</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Hospital Felício Rocho, Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Int Arch Otorhinolaryngol</MedlineTA><NlmUniqueID>101637652</NlmUniqueID><ISSNLinking>1809-4864</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">chloroquine</Keyword><Keyword MajorTopicYN="N">hearing loss</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">ototoxicity</Keyword></KeywordList><CoiStatement>Conflict of Interests The authors declare that there was no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32774508</ArticleId><ArticleId IdType="doi">10.1055/s-0040-1714142</ArticleId><ArticleId IdType="pii">200153</ArticleId><ArticleId IdType="pmc">PMC7402412</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CMAJ. 2020 Apr 27;192(17):E450-E453</Citation><ArticleIdList><ArticleId IdType="pubmed">32269021</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 1983 Apr;15(4):502-3</Citation><ArticleIdList><ArticleId IdType="pubmed">6849790</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 May 11;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32392282</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Rheum Dis. 2011 Feb;14(1):e1-2</Citation><ArticleIdList><ArticleId IdType="pubmed">21303469</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2001 May 15;55(2):197-203</Citation><ArticleIdList><ArticleId IdType="pubmed">11470315</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Otolaryngol. 1968 Oct;88(4):370-2</Citation><ArticleIdList><ArticleId IdType="pubmed">5302911</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 22;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32450107</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Laryngol Otol. 1979 Aug;93(8):809-15</Citation><ArticleIdList><ArticleId IdType="pubmed">490032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ear Nose Throat J. 2014 Jul;93(7):256-64</Citation><ArticleIdList><ArticleId IdType="pubmed">25025411</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Otolaryngol. 2020 May - Jun;41(3):102483</Citation><ArticleIdList><ArticleId IdType="pubmed">32307189</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Med. 2020 Mar 31;9(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">32244365</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Toxicol In Vitro. 2019 Apr;56:150-155</Citation><ArticleIdList><ArticleId IdType="pubmed">30654088</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):889-890</Citation><ArticleIdList><ArticleId IdType="pubmed">32215618</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2020 May 14;369:m1849</Citation><ArticleIdList><ArticleId IdType="pubmed">32409561</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Rheumatol. 2007 Nov;26(11):1809-10</Citation><ArticleIdList><ArticleId IdType="pubmed">17594118</ArticleId></ArticleIdList></Reference><Reference><Citation>Daru. 2014 Jan 22;22(1):20</Citation><ArticleIdList><ArticleId IdType="pubmed">24450358</ArticleId></ArticleIdList></Reference><Reference><Citation>An Bras Dermatol. 2018 Jun;93(3):469-470</Citation><ArticleIdList><ArticleId IdType="pubmed">29924251</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Otolaryngol. 1975 Mar;101(3):185-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1120003</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101623</Citation><ArticleIdList><ArticleId IdType="pubmed">32179124</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2020 Jul 21;173(2):137-142</Citation><ArticleIdList><ArticleId IdType="pubmed">32422063</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2011 Mar 1;203(5):691-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21199881</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Tinnitus J. 2014;19(1):68-76</Citation><ArticleIdList><ArticleId IdType="pubmed">27186836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ear Nose Throat J. 2020 Apr 13;:145561320920762</Citation><ArticleIdList><ArticleId IdType="pubmed">32283980</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F21 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000F21 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32774508
|texte= Chloroquine and COVID-19: Should We Care about Ototoxicity?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32774508" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |